A meta-analysis of randomized head-to-head trials for effects of rosuvastatin versus atorvastatin on apolipoprotein profiles

American Journal of Cardiology

Volumn 113, Issue 2, 2014, Pages 292-301

  Takagi, Hisato ^a   Umemoto, Takuya ^a  

^a SHIZUOKA MEDICAL CENTER   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN; APOLIPOPROTEIN A1; APOLIPOPROTEIN B; ATORVASTATIN; ROSUVASTATIN;

ARTICLE; DRUG EFFECT; DRUG MEGADOSE; HUMAN; META ANALYSIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC);

EID: 84891623619     PISSN: 00029149     EISSN: 18791913     Source Type: Journal    
DOI: 10.1016/j.amjcard.2013.08.043     Document Type: Article

References (17)

1. G. Walldius, and I. Jungner Rationale for using apolipoprotein B and apolipoprotein A-I as indicators of cardiac risk and as targets for lipid-lowering therapy Eur Heart J 26 2005 210 212
2. G. Walldius, and I. Jungner Apolipoprotein B and apolipoprotein A-I: risk indicators of coronary heart disease and targets for lipid-modifying therapy J Intern Med 255 2004 188 205
3. A. Thompson, and J. Danesh Associations between apolipoprotein B, apolipoprotein AI, the apolipoprotein B/AI ratio and coronary heart disease: a literature-based meta-analysis of prospective studies J Intern Med 259 2006 481 492
4. S.M. Boekholdt, B.J. Arsenault, S. Mora, T.R. Pedersen, J.C. LaRosa, P.J. Nestel, R.J. Simes, P. Durrington, G.A. Hitman, K.M. Welch, D.A. DeMicco, A.H. Zwinderman, M.B. Clearfield, J.R. Downs, A.M. Tonkin, H.M. Colhoun, A.M. Gotto Jr., P.M. Ridker, and J.J. Kastelein Association of LDL cholesterol, non-HDL cholesterol, and apolipoprotein B levels with risk of cardiovascular events among patients treated with statins: a meta-analysis JAMA 307 2012 1302 1309
5. J. Wlodarczyk, D. Sullivan, and M. Smith Comparison of benefits and risks of rosuvastatin versus atorvastatin from a meta-analysis of head-to-head randomized controlled trials Am J Cardiol 102 2008 1654 1662
6. S.J. Nicholls, G. Brandrup-Wognsen, M. Palmer, and P.J. Barter Meta-analysis of comparative efficacy of increasing dose of atorvastatin versus rosuvastatin versus simvastatin on lowering levels of atherogenic lipids (from VOYAGER) Am J Cardiol 105 2010 69 76
7. P.J. Barter, G. Brandrup-Wognsen, M.K. Palmer, and S.J. Nicholls Effect of statins on HDL-C: a complex process unrelated to changes in LDL-C: analysis of the VOYAGER Database J Lipid Res 51 2010 1546 1553
8. D. Moher, D.J. Cook, S. Eastwood, I. Olkin, D. Rennie, and D.F. Stroup Improving the quality of reports of meta-analyses of randomised controlled trials: the QUOROM statement. Quality of Reporting of Meta-analyses Lancet 354 1999 1896 1900
9. J.P. Higgins, and J.J. Deeks Selecting studies and collecting data J.P. Higgins, S. Green, Cochrane Handbook for Systematic Reviews of Interventions, Version 5.1.0 (Updated March 2011) 2011 The Cochrane Collaboration Available at: www.cochrane-handbook.org Accessed June 30, 2013
10. J.P. Higgins, J.J. Deeks, and D.G. Altman Special topics in statistics J.P. Higgins, S. Green, Cochrane Handbook for Systematic Reviews of Interventions, Version 5.1.0 (Updated March 2011) 2011 The Cochrane Collaboration Available at: www.cochrane-handbook.org Accessed June 30, 2013
11. D. Follmann, P. Elliott, I. Suh, and J. Cutler Variance imputation for overviews of clinical trials with continuous response J Clin Epidemiol 45 1992 769 773
12. T.C. Weng, Y.H. Yang, S.J. Lin, and S.H. Tai A systematic review and meta-analysis on the therapeutic equivalence of statins J Clin Pharm Ther 35 2010 139 151
13. H. Naci, J. Brugts, and T. Ades Comparative tolerability and harms of individual statins: a study-level network meta-analysis of 246 955 participants from 135 randomized, controlled trials Circ Cardiovasc Qual Outcomes 6 2013 390 399
14. A.D. Sniderman, K. Williams, J.H. Contois, H.M. Monroe, M.J. McQueen, J. de Graaf, and C.D. Furberg A meta-analysis of low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol, and apolipoprotein B as markers of cardiovascular risk Circ Cardiovasc Qual Outcomes 4 2011 337 345
15. J.H. Contois, J.P. McConnell, A.A. Sethi, G. Csako, S. Devaraj, D.M. Hoefner, G.R. Warnick, and AACC Lipoproteins and Vascular Diseases Division Working Group on Best Practices Apolipoprotein B and cardiovascular disease risk: position statement from the AACC Lipoproteins and Vascular Diseases Division Working Group on Best Practices Clin Chem 55 2009 407 419
16. J.G. Robinson, S. Wang, and T.A. Jacobson Meta-analysis of comparison of effectiveness of lowering apolipoprotein B versus low-density lipoprotein cholesterol and nonhigh-density lipoprotein cholesterol for cardiovascular risk reduction in randomized trials Am J Cardiol 110 2012 1468 1476
17. J.J. Deeks, J.P. Higgins, and D.G. Altman Analysing data and undertaking meta-analyses J.P. Higgins, S. Green, Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (Updated March 2011) 2011 The Cochrane Collaboration Available at: www.cochrane-handbook.org Accessed June 30, 2013